

Claim Amendments

Please amend the claims as shown in the list below.

- Claim 1. (Original) Fexofenadine hydrochloride characterized by a PXRD pattern with peaks at about 4.7, 9.3, 17.4, 18.2, 19.4, 19.6, 21.6 and 24.0 ± 0.2 degrees two theta.
- Claim 2. (Currently amended) The fexofenadine hydrochloride of claim 1, wherein
the having a PXRD pattern is substantially as depicted in Fig. 6.
- Claim 3. (Original) Fexofenadine hydrochloride Form IX.
- Claim 4. (Withdrawn) A fexofenadine hydrochloride MTBE solvate.
- Claim 5. (Withdrawn) A fexofenadine hydrochloride Form IX-MTBE solvate.
- Claim 6. (Withdrawn) A fexofenadine hydrochloride MTBE solvate characterized by a DTG profile with endotherms at about 100°C and about 125°C.
- Claims 7 – 9. (Cancelled)
- Claim 10. (Withdrawn) A process for preparing fexofenadine hydrochloride Form IX comprising the steps of:
- a) preparing a solution of fexofenadine hydrochloride in acetone;
 - b) adding the solution to an anti-solvent selected from the group consisting of MTBE and cyclohexane to form a precipitate; and
 - c) separating the precipitate as a solvate of the anti-solvent used.
- Claim 11. (Withdrawn) The process of claim 10, further comprising drying the solvate.
- Claim 12. (Withdrawn) A process for preparing fexofenadine hydrochloride Form IX

comprising the steps of:

- a) preparing a solution of fexofenadine hydrochloride in ethanol;
- b) adding the solution to an anti-solvent selected from the group consisting of MTBE and cyclohexane to form a precipitate; and
- c) separating the precipitate as a solvate of the anti-solvent used.

Claim 13. (Withdrawn) The process of claim 12, further comprising drying the solvate.

Claim 14. (Currently amended) A pharmaceutical composition comprising:

- a) solid fexofenadine hydrochloride selected from the group consisting of Form IX-MTBE solvate and Form IX-cyclohexane solvate; and
- b) a pharmaceutically acceptable excipient.

Claim 15. (Original) A unit dosage of the pharmaceutical composition of claim 14 containing about 30 to about 180 mg of fexofenadine hydrochloride.

Claim 16. (Original) A method of inhibiting binding between an H₁ receptor and histamine in a mammal comprising administering the pharmaceutical composition of claim 14 to the mammal.